Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Furthermore, these individuals were more likely to have elevated levels of vitamin D (p < 0.001) and magnesium (p = 0.014).

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Our retrospective cohort study included a total of 6,212 patients diagnosed with either EOAD or LOAD from February 2016 to August 2020.

Source: Abstract.

Patients were classified as having AD using a combination of cognitive and neurological testing (MOCA, MMSE, etc.) and brain imaging (MRI, MRA, CT, CTA, etc.).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Sex differences in clinical risk factors for Alzheimer's dementia patients with early-onset and late-onset

Cohort study · Frontiers in Global Women's Health · 2025

Original publication title

Sex differences in clinical risk factors for Alzheimer's dementia patients with early-onset and late-onset

Nathan Gerhard Faulstich; Sammy Hilmi Omar; Connor John O-brien; Dami Taiwo Ojo; Philip Cole Brewer; Emmanuel I. Nathaniel; Richard Goodwin; Laurie Roley; Adebobola Imeh-Nathaniel; Thomas I. Nathaniel

© 2025 Faulstich, Hilmi Omar, John O-brien, Ojo, Brewer, Nathaniel, Goodwin, Roley, Imeh-Nathaniel and Nathaniel.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Our findings indicate sex differences in the risk factors for EAOD and LOAD patients. Understanding these risk factors can help us develop strategies to improve diagnostic accuracy, create targeted interventions, and enhance clinical outcomes for both male and female EAOD and LOAD patients.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

The objective of this study is to identify the risk factors that contribute to sex differences in patients with Alzheimer dementia (AD), specifically focusing on Early-Onset Alzheimer's Dementia (EAOD) and Late-Onset Alzheimer Dementia (LOAD). Additionally, the study aims to determine whether these risk factors differ between male and female EAOD and LOAD patients.

Source: Background

Abstract: What methods does the paper describe?

Our retrospective cohort study included a total of 6,212 patients diagnosed with either EOAD or LOAD from February 2016 to August 2020. Among this population, 687 patients (11.06%) were diagnosed with EOAD, while 5,525 patients (88.94%) had LOAD. We conducted a univariate analysis to identify differences in risk factors between male and female AD patients. A multivariate analysis was also performed to predict specific risk factors associated with male and female EOAD and LOAD patients.

Source: Methods

Abstract: Results

In the adjusted analysis, males with LOAD were found to have significantly higher odds of several comorbidities, including dyslipidemia [Odds Ratio (OR) = 1.720, 95% Confidence Interval (CI) = 1.489 to 1.987, p < 0.001], peripheral vascular disease (OR = 2.324, 95% CI = 1.828 to 2.955, p < 0.001), obstructive sleep apnea (OR = 2.330, 95% CI = 1.768 to 3.070, p < 0.001), and pneumonia (OR = 1.235, 95% CI = 1.004 to 1.520, p = 0.046). In contrast, females with LOAD were associated with lower odds of having hypertension (OR = 0.715, 95% CI = 0.623 to 0.820, p < 0.001), osteoporosis (OR = 0.310, 95% CI = 0.254 to 0.380, p < 0.001), urinary tract infections (OR = 0.638, 95% CI = 0.521 to 0.782, p < 0.001), congestive heart failure (OR = 0.626, 95% CI = 0.481 to 0.815, p < 0.001), and rheumatoid arthritis.

In male patients with EAOD the analysis indicated a strong association with gait dysfunction (OR = 10.797, 95% CI = 3.257 to 35.792, p < 0.001), peripheral vascular disease (OR = 3.835, 95% CI = 1.767 to 8.321, p < 0.001), and Chronic Obstructive Pulmonary Disease (COPD) (OR = 5.984, 95% CI = 2.186 to 16.381, p < 0.001). Conversely, females with EOAD were associated with significantly lower odds of experiencing cerebrovascular accidents (OR = 0.347, 95% CI = 0.155 to 0.778, p < 0.001), osteoporosis (OR = 0.345, 95% CI = 0.155 to 0.778, p = 0.030), and anxiety (OR = 0.412, 95% CI = 0.203 to 0.833, p = 0.014).

Source: Results

Abstract: Conclusions

Our findings indicate sex differences in the risk factors for EAOD and LOAD patients. Understanding these risk factors can help us develop strategies to improve diagnostic accuracy, create targeted interventions, and enhance clinical outcomes for both male and female EAOD and LOAD patients.

Source: Conclusions
Authors’ abstract

Background

The objective of this study is to identify the risk factors that contribute to sex differences in patients with Alzheimer dementia (AD), specifically focusing on Early-Onset Alzheimer's Dementia (EAOD) and Late-Onset Alzheimer Dementia (LOAD). Additionally, the study aims to determine whether these risk factors differ between male and female EAOD and LOAD patients.

Methods

Our retrospective cohort study included a total of 6,212 patients diagnosed with either EOAD or LOAD from February 2016 to August 2020. Among this population, 687 patients (11.06%) were diagnosed with EOAD, while 5,525 patients (88.94%) had LOAD. We conducted a univariate analysis to identify differences in risk factors between male and female AD patients. A multivariate analysis was also performed to predict specific risk factors associated with male and female EOAD and LOAD patients.

Results

In the adjusted analysis, males with LOAD were found to have significantly higher odds of several comorbidities, including dyslipidemia [Odds Ratio (OR) = 1.720, 95% Confidence Interval (CI) = 1.489 to 1.987, p < 0.001], peripheral vascular disease (OR = 2.324, 95% CI = 1.828 to 2.955, p < 0.001), obstructive sleep apnea (OR = 2.330, 95% CI = 1.768 to 3.070, p < 0.001), and pneumonia (OR = 1.235, 95% CI = 1.004 to 1.520, p = 0.046). In contrast, females with LOAD were associated with lower odds of having hypertension (OR = 0.715, 95% CI = 0.623 to 0.820, p < 0.001), osteoporosis (OR = 0.310, 95% CI = 0.254 to 0.380, p < 0.001), urinary tract infections (OR = 0.638, 95% CI = 0.521 to 0.782, p < 0.001), congestive heart failure (OR = 0.626, 95% CI = 0.481 to 0.815, p < 0.001), and rheumatoid arthritis.

In male patients with EAOD the analysis indicated a strong association with gait dysfunction (OR = 10.797, 95% CI = 3.257 to 35.792, p < 0.001), peripheral vascular disease (OR = 3.835, 95% CI = 1.767 to 8.321, p < 0.001), and Chronic Obstructive Pulmonary Disease (COPD) (OR = 5.984, 95% CI = 2.186 to 16.381, p < 0.001). Conversely, females with EOAD were associated with significantly lower odds of experiencing cerebrovascular accidents (OR = 0.347, 95% CI = 0.155 to 0.778, p < 0.001), osteoporosis (OR = 0.345, 95% CI = 0.155 to 0.778, p = 0.030), and anxiety (OR = 0.412, 95% CI = 0.203 to 0.833, p = 0.014).

Conclusions

Our findings indicate sex differences in the risk factors for EAOD and LOAD patients. Understanding these risk factors can help us develop strategies to improve diagnostic accuracy, create targeted interventions, and enhance clinical outcomes for both male and female EAOD and LOAD patients.

Publication and source details

Original title: Sex differences in clinical risk factors for Alzheimer's dementia patients with early-onset and late-onset

Nathan Gerhard Faulstich; Sammy Hilmi Omar; Connor John O-brien; Dami Taiwo Ojo; Philip Cole Brewer; Emmanuel I. Nathaniel; Richard Goodwin; Laurie Roley; Adebobola Imeh-Nathaniel; Thomas I. Nathaniel

Frontiers in Global Women's Health · 2025

Edited by: Xiaohui Sem, Women in Global Health Singapore, Singapore

Reviewed by: Roberta Marongiu, Cornell University, United States

Cecilia Boccalini, University of Geneva, Switzerland

* Correspondence: Thomas I. Nathaniel nathanit@greenvillemed.sc.edu
© 2025 Faulstich, Hilmi Omar, John O-brien, Ojo, Brewer, Nathaniel, Goodwin, Roley, Imeh-Nathaniel and Nathaniel.2025Faulstich, Hilmi Omar, John O-brien, Ojo, Brewer, Nathaniel, Goodwin, Roley, Imeh-Nathaniel and Nathanielhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declare that no financial support was received for the research and/or publication of this article.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:37:28.340773+00:00

DOI: 10.3389/fgwh.2025.1601375 · PMC12358484